Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 6
Submit an article Journal homepage
3,508
Views
9
CrossRef citations to date
0
Altmetric
Editorials

Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam’s Razor?

Ashish Sharmaa Lotus Eye Hospital and Institute, Coimbatore, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8550-9791
, MDORCID Icon,
Nilesh Kumara Lotus Eye Hospital and Institute, Coimbatore, IndiaORCID Iconhttps://orcid.org/0000-0002-7439-2081
, MDORCID Icon,
Nikulaa Parachuria Lotus Eye Hospital and Institute, Coimbatore, India
, MD,
Sonali Singhb Ocular Pathologist, Madhavi Netralaya, Ara, India
, MD,
Francesco Bandelloc Scientific Institute San Raffaele, University Vita-Salute, Milano, ItalyORCID Iconhttps://orcid.org/0000-0003-3238-9682
, MDORCID Icon,
Carl D. Regillod Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA
, MD,
David Boyere Retina Vitreous Associates Medical Group, Los Angeles, California, USA
, MD &
Quan Dong Nguyenf Byers Eye Institute, Stanford University, Palo Alto, California, USA
, MD show all
Pages 1508-1510 | Received 12 Jan 2021, Accepted 25 Feb 2021, Published online: 20 May 2021

References

  • Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology: 2020;127(1):72–84.
  • Sharma A, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Brolucizumab: is extended VEGF suppression on the horizon? Eye (Lond). 2020;34(3):424–426.
  • Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab—leading an era of structural revolution for long-term VEGF suppression. Eye (Lond). 2020;34(4):611–613.
  • Jain A, Chea S, Matsumiya W. et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. doi:10.1016/j.ajoc.2020.100687.
  • Haug SJ, Hien DL, Uludag G. et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. doi:10.1016/j.ajoc.2020.100680.
  • Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359.
  • Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi:10.1177/2474126420930863.
  • Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20:100989. doi:10.1016/j.ajoc.2020.100989.
  • US FDA approves updated Novartis Beovu® label, to include additional safety information. Novartis. https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information. Accessed June 19, 2020
  • Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab. Ophthalmology. S0161642020310757. Published online November 2020. doi:10.1016/j.ophtha.2020.11.011.
  • Safety of Beovu® (brolucizumab). https://www.brolucizumab.info/. Accessed June 19, 2020.
  • Novartis Pharmaceuticals Corporation. Beovu (brolucizumab-dll) [package insert]. U.S. Food and Drug Administration .https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf. Revised October 7,2019. Accessed June 19, 2020.
  • Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and/or vascular occlusion after brolucizumab treatment. Ophthalmol Retina. S2468653020304000. Published online September 2020. doi:10.1016/j.oret.2020.09.020.
  • Rosenbaum JT, Ku J, Ali A, Choi D, Suhler EB. Patients with retinal vasculitis rarely suffer from systemic vasculitis. Semin Arthritis Rheum. 2012;41(6):859–865. doi:10.1016/j.semarthrit.2011.10.006.
  • Sharma A, Kumar N, Parachuri N, et al. Brolucizumab and immunogenicity. Eye (Lond).2020;34(10):1726–1728.
  • Baldo B. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. OncoImmunology. 2013;2(10):e26333. doi:10.4161/onci.26333.
  • Isabwe GAC, Garcia Neuer M, De Las Vecillas Sanchez L, D-m L, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142(1):159–170.e2. doi:10.1016/j.jaci.2018.02.018.
  • Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol. 2014;42(1):293–300. doi:10.1177/0192623313510987.
  • Genentech, Inc. Lucentis (ranibizumab)[package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf. Revised October 2014. Accessed June 19, 2020.
  • Regeneron Pharmaceuticals, Inc. Eylea (aflibercept)[package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf. Revised November 2011. Accessed June 19, 2020.
  • Holland MC, Wurthner JU, Morley PJ, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33(7):1192–1203. doi:10.1007/s10875-013-9915-0.
  • Jefferis R. Aggregation, immune complexes and immunogenicity. mAbs. 2011;3(6):503–504. doi:10.4161/mabs.3.6.17611.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.